Literature DB >> 26798

Inhibition of sympathetic nervous system by histamine:studies with H1- and H2-receptor antagonists.

M F Lokhandwala.   

Abstract

A study was designed to investigate the effect of histamine on sympathetic transmission to the myocardium in pentobarbital-anesthetized dogs. Intravenous infusion of histamine (1.0 and 2.0 microgram/kg/min) produced dose-related decreases in blood pressure and caused significant impairment of cardioacceleration observed during stimulation of the right postganglionic cardiac sympathetic nerve fibers. Positive chronotropic effects of intravenously administered norepinephrine as well as tyramine were not altered during histamine infusion. Blockade of neuronal reuptake with desipramine did not modify the inhibitory action of histamine on sympathetic nerve function. Prior administration of mepyramine (pyrilamine), a histamine type H1-receptor antagonist caused partial attenuation of the depressor action of histamine, but did not prevent histamine-induced inhibition of neurogenic function. Further treatment with metiamide, a histamine type H2-receptor antagonist caused nearly complete attenuation of the depressor response to histamine and also significantly antagonized the inhibitory action of histamine on sympathetic transmission to the myocardium. It is concluded that while the depressor action of histamine is due to the activation of both H1- as well as H2-receptors, histamine causes impairment of sympathetic nerve function to the myocardium by acting on H2-receptors which may be located on sympathetic nerve terminals.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 26798

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  16 in total

1.  Cardiovascular effects of the novel histamine H2 receptor agonist amthamine: interaction with the adrenergic system.

Authors:  G Coruzzi; E Gambarelli; G Bertaccini; H Timmerman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-03       Impact factor: 3.000

2.  Adrenalectomy modifies the effect of intracerebral histamine on the cold-stimulated TSH secretion in male rats.

Authors:  R K Tuominen; P T Männistö
Journal:  Agents Actions       Date:  1986-08

3.  Effects of histamine on the guinea-pig stomach: excitation of smooth muscle and inhibition of transmitter release.

Authors:  H Ono; H Suzuki
Journal:  Br J Pharmacol       Date:  1987-08       Impact factor: 8.739

4.  H1-receptor antagonists: comparative pharmacology and clinical use.

Authors:  D Reinhardt; U Borchard
Journal:  Klin Wochenschr       Date:  1982-09-01

5.  Prejunctional inhibition of sympathetically evoked pupillary dilation in cats by activation of histamine H3 receptors.

Authors:  M C Koss; J A Hey
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-08       Impact factor: 3.000

6.  Inotropic effects of ranitidine.

Authors:  E C Meyer; D K Sommers; M van Wyk; J C Avenant
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

7.  In vivo release by histamine agonists and antagonists of endogenous catecholamines in the cat hypothalamus.

Authors:  A Philippu; M Bald; A Kraus; H Dietl
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-06       Impact factor: 3.000

8.  Chronotropic cardiac effects of histamine in the conscious dog with chronic atrioventricular block: interactions with the autonomic nervous system.

Authors:  J H Li; M Boucher; P Duchene-Marullaz
Journal:  Agents Actions       Date:  1986-11

9.  Inhibition of noradrenaline release from the sympathetic nerves of the human saphenous vein by presynaptic histamine H3 receptors.

Authors:  G J Molderings; G Weissenborn; E Schlicker; J Likungu; M Göthert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-07       Impact factor: 3.000

10.  Identification of endothelial H1, vascular H2 and cardiac presynaptic H3 receptors in the pithed rat.

Authors:  B Malinowska; E Schlicker
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-01       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.